{
    "clinical_study": {
        "@rank": "23454", 
        "arm_group": [
            {
                "arm_group_label": "Minhai Bio", 
                "arm_group_type": "Experimental", 
                "description": "0.5 ml/ dose, containing 50 \u03bcg of each antigen."
            }, 
            {
                "arm_group_label": "Hualan Bio", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5 ml/ dose, containing 50 \u03bcg of each antigen."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this double-blind study is to evaluate the safety, reactogenicity and\n      immunogenicity of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine in 2 to 30\n      years-old Children and Adults. Subjects will be vaccinated once."
        }, 
        "brief_title": "Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningitis", 
        "condition_browse": {
            "mesh_term": "Meningitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes will comply with the requirements of the\n             protocol should be enrolled in the study.\n\n          -  Healthy permanent residence 2-30 years old.\n\n          -  Subjects and parent/guardian able to attend all scheduled visits and comply with all\n             study procedures.\n\n          -  Axillary temperature \u226437.0 \u2103.\n\n        Exclusion Criteria:\n\n          -  History of meningitis infection or vaccination of meningococcal vaccine within the\n             past 6 months.\n\n          -  Allergic history or any SAE after vaccination, such as allergy, urticaria, dyspnea,\n             angioedema, celialgia.\n\n          -  Patients administered with immunosuppressive agents, cytotoxicity factor or\n             corticosteroids in the 6 months preceding the vaccine trial.\n\n          -  Receipt of blood or blood-derived products in the 3 months preceding vaccination.\n\n          -  Participation in another clinical study investigating a vaccine, drug in the 30 days\n             preceding vaccination.\n\n          -  Receipt of any live virus vaccine in the 15 days preceding vaccination.\n\n          -  Receipt of any subunit vaccine and inactivated vaccine in the 7 days before\n             vaccination.\n\n          -  Febrile illness (temperature \u2265 38\u00b0C) in the 3 days or any acute illness/infection in\n             the 7 days preceding vaccination.\n\n          -  Thrombocytopenia.\n\n          -  History of thyroid gland excision or treatment for thyroid gland disease in last 12\n             months.\n\n          -  Functional or anatomic asplenia.\n\n          -  History of eclampsia, epilepsy, encephalopathy and mental disease or family disease.\n\n          -  Chronic disease (such as Down syndrome, diabetes, sickle cell anemia or neurologic\n             disease, Guillain-Barre Syndrome).\n\n          -  Known or suspected diseases, including: respiratory system disease, acute infection\n             or active stage of chronic disease, HIV infection of children or mothers,\n             cardiovascular disease, acute hypertension, cancer treatment, skin disease, etc.\n\n          -  In pregnancy or lactation or pregnant women during the test plan\n\n          -  Any condition that, in the judgment of investigator, may affect trial assessment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "30 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "1260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003313", 
            "org_study_id": "2012L02647", 
            "secondary_id": "2012L02647"
        }, 
        "intervention": [
            {
                "arm_group_label": "Minhai Bio", 
                "description": "Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine", 
                "intervention_name": "Minhai Bio", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Hualan Bio", 
                "description": "Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine", 
                "intervention_name": "Hualan Bio", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "safety, immunogenicity, Meningococcal Polysaccharide Vaccine", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "shinianmin@sina.com", 
                "last_name": "nianmin shi", 
                "phone": "86-10-67773548"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100021"
                }, 
                "name": "Chaoyang District Centre for Disease Prevention and Control"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine in More Than 2 Years Old Children and Adults", 
        "overall_contact": {
            "email": "guifan@sohu.com", 
            "last_name": "Guifan Li", 
            "phone": "86-10-59613591"
        }, 
        "overall_official": {
            "affiliation": "Beijing chaoyang district center for disease control and prevention", 
            "last_name": "nianmin shi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects exhibiting a >= 4fold increase in rSBA titers level from pre-vaccination to post-vaccination", 
            "safety_issue": "No", 
            "time_frame": "28 days after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003313"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "to evaluate the adverse reactions after vaccination", 
            "safety_issue": "Yes", 
            "time_frame": "28 days after vaccination"
        }, 
        "source": "Beijing Minhai Biotechnology Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Minhai Biotechnology Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}